We are live on ! Find out more

ALPS Medical Breakthroughs ETF

SBIO

Market cap $189M

54.87 USD

-1.16

2.07%

At close Updated Oct 30, 4:00 PM EDT

1 day

-2.07%

5 days

2.37%

1 month

-5.88%

3 months

-15.84%

6 months

2.35%

Year to date

9.39%

1 year

22.75%

5 years

15.49%

10 years

151.35%

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 57.1%

Neutral 42.9%

Negative 0%

Biotech ETF SBIO Can Get Its Groove Back

With rising Treasury yields and the Federal Reserve's recent interest rate hike ranking as the likely culprits, the previously hot ALPS Medical Breakthroughs ETF (SBIO) is in the midst of a correction. That pullback, though, may be a buying opportunity.

Biotech ETF SBIO Can Get Its Groove Back

SBIO: Promising Pipelines, Insufficient Return Potential

SBIO is rated Sell due to a significant overvaluation vs. its probability-weighted fair NAV of $37.86, far below the $62.22 market price. Current fund pricing capitalizes on large portions of future biotech success, exposing investors to downside if clinical or commercial outcomes disappoint. Despite credible late-stage pipelines and solid cash runways, dilution risk remains high, with modeled scenarios projecting negative annualized returns.

SBIO: Promising Pipelines, Insufficient Return Potential

SBIO: Big Pharma Needs What This Fund Owns

The ALPS Medical Breakthroughs ETF targets late-stage biotech firms primed for clinical catalysts and acquisition interest. SBIO's methodology requires at least one Phase II/III program and 24 months of cash, reducing dilution risk before key events. Recent acquisitions of top holdings post-August highlight SBIO's ability to capture M&A-driven upside and recycle capital into new prospects.

SBIO: Big Pharma Needs What This Fund Owns

SBIO ETF Rallies on Clinical Trial Wins & M&A Demand

The biotechnology sector continues to ride a massive wave of medical innovation, and ETFs like the ALPS Medical Breakthroughs ETF (SBIO) appear to be capturing the upside. SBIO posted a solid 5% gain in August, fueled by positive clinical trial data and an accelerating pace of industry mergers and acquisitions.

SBIO ETF Rallies on Clinical Trial Wins & M&A Demand

Zacks Investment Research

Should You Invest in the ALPS Medical Breakthroughs ETF (SBIO)?

If you're interested in broad exposure to the Healthcare - Broad segment of the equity market, look no further than the ALPS Medical Breakthroughs ETF (SBIO), a passively managed exchange traded fund launched on December 31, 2014.

Should You Invest in the ALPS Medical Breakthroughs ETF (SBIO)?

Sabio Holdings Inc. (SBIO:CA) Q2 2026 Earnings Call Transcript

Sabio Holdings Inc. (SBIO:CA) Q2 2026 Earnings Call Transcript

Sabio Holdings Inc. (SBIO:CA) Q2 2026 Earnings Call Transcript

3 Small-Cap ETFs to Watch as Russell 2000 Hits Record

The Russell 2000 closed at a new record high Friday amid continued upwards momentum for several market indexes. That index, with its focus on small-caps, could prove an intriguing source of investing opportunities, given the right approach.

3 Small-Cap ETFs to Watch as Russell 2000 Hits Record

Risk-Wary Family Offices Double Down on Infrastructure

Geopolitical shocks have pushed family offices to rethink nearly every corner of their portfolios. Infrastructure has emerged as the asset class they trust most right now.

Risk-Wary Family Offices Double Down on Infrastructure

Big Pharma's $300 Billion Patent Problem Fuels Biotech Deals

Big Pharma has a $300 billion problem, and biotech developers with promising drugs are becoming the fix. Major drugmakers are spending at a pace not seen since 2019 to replace medicines that will soon lose patent protection.

Big Pharma's $300 Billion Patent Problem Fuels Biotech Deals

Zacks Investment Research

Should You Invest in the ALPS Medical Breakthroughs ETF (SBIO)?

Designed to provide broad exposure to the Healthcare - Broad segment of the equity market, the ALPS Medical Breakthroughs ETF (SBIO) is a passively managed exchange traded fund launched on December 31, 2014.

Should You Invest in the ALPS Medical Breakthroughs ETF (SBIO)?

See News Rankings

Price charts implemented using Lightweight Charts™